Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Share-based Compensation (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Share-based Compensation for 16 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 383.97% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.8 million, a 60.87% decrease, with the full-year FY2023 number at $7.3 million, down 45.53% from a year prior.
  • Share-based Compensation was $1.1 million for Q3 2025 at Gyre Therapeutics, up from $906000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.3 million in Q4 2022 to a low of $11000.0 in Q1 2024.
  • A 5-year average of $1.5 million and a median of $511000.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 94.76% in 2024, then soared 5562.5% in 2025.
  • Gyre Therapeutics' Share-based Compensation stood at $683000.0 in 2021, then skyrocketed by 1698.1% to $12.3 million in 2022, then crashed by 43.95% to $6.9 million in 2023, then tumbled by 96.56% to $237000.0 in 2024, then soared by 383.97% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Share-based Compensation are $1.1 million (Q3 2025), $906000.0 (Q2 2025), and $507000.0 (Q1 2025).